Insider Selling: Catalent, Inc. (NYSE:CTLT) SVP Sells $19,190.40 in Stock

Catalent, Inc. (NYSE:CTLT - Get Free Report) SVP Joseph Anthony Ferraro sold 320 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $59.97, for a total value of $19,190.40. Following the transaction, the senior vice president now owns 23,967 shares of the company's stock, valued at approximately $1,437,300.99. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Catalent Stock Down 0.1 %

Shares of NYSE CTLT traded down $0.09 during mid-day trading on Monday, reaching $60.20. The company had a trading volume of 772,640 shares, compared to its average volume of 2,041,459. The firm has a 50 day simple moving average of $60.12 and a two-hundred day simple moving average of $57.79. Catalent, Inc. has a 52-week low of $31.80 and a 52-week high of $61.20. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. The stock has a market cap of $10.89 billion, a P/E ratio of -9.88, a PEG ratio of 2.14 and a beta of 1.15.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. Sell-side analysts predict that Catalent, Inc. will post 0.95 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on CTLT shares. Baird R W lowered shares of Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Barclays raised their price target on Catalent from $47.00 to $63.00 and gave the stock an "equal weight" rating in a research report on Friday, June 28th. Robert W. Baird reaffirmed a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Royal Bank of Canada reissued a "sector perform" rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Finally, William Blair reaffirmed a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Nine investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Catalent has a consensus rating of "Hold" and an average target price of $59.83.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC increased its holdings in shares of Catalent by 12.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 9,745 shares of the company's stock valued at $590,000 after acquiring an additional 1,058 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Catalent by 1.1% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company's stock worth $1,179,000 after purchasing an additional 220 shares during the last quarter. Kapitalo Investimentos Ltda acquired a new stake in shares of Catalent in the 3rd quarter valued at about $808,000. Creative Planning lifted its position in shares of Catalent by 21.4% during the third quarter. Creative Planning now owns 6,935 shares of the company's stock worth $420,000 after purchasing an additional 1,222 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. grew its stake in Catalent by 57.5% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company's stock worth $72,000 after purchasing an additional 431 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.